Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
national blog main
san diego blog main
san diego top stories
4
×
biotech
boston blog main
boston top stories
fda
new york blog main
drugs
national top stories
new york top stories
achaogen
adams street partners
akcea therapeutics
alder biopharmaceuticals
amgen
antibiotics
anylam pharmaceuticals
beta lactamase inhibitor
biomedical advanced research and development authority (barda)
biotech ipos
boston
boulder/denver blog main
boulder/denver top stories
calcitonin gene-related peptide
cardiomyopathy
chronic migraine
david rind
deals
detroit blog main
detroit top stories
drug resistance
dyne therapeutics
eli lilly
episodic migraine
eptinezumab
erenumab
food and drug administration
What
drug
4
×
medicines
4
×
company
disease
fda
genetic
rare
therapeutics
year
ago
akcea
alnylam
amgen
amyloidosis
approval
approved
attr
available
bacteria
battle
biopharma
brings
business
candidates
class
debilitating
developed
developing
disorders
dyne
dyne’s
exited
fighting
gets
head
infections
infectious
ipo
launches
melinta
Language
unset
Current search:
drug
×
medicines
×
" san diego top stories "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines